Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Signifor Pasireotide diaspartate Cushing’s disease Do not list Complete
Signifor LAR pasireotide ​Acromegaly, adults Active
Siliq brodalumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete
Silkis Calcitriol Psoriasis, mild to moderate plaque Do not list Complete
Simbrinza Brinzolamide / brimonidine Glaucoma and ocular hypertension List Complete
Simponi Golimumab Arthritis, Rheumatoid List in a similar manner Complete
Simponi Golimumab Arthritis, psoriatic List in a similar manner Complete
Simponi Golimumab Ankylosing spondylitis List in a similar manner Complete
Simponi Golimumab Ulcerative colitis Do not list at the submitted price Complete
Simponi I.V. Golimumab Arthritis, rheumatoid List with criteria/condition Complete